Scarica l'app Stockscreener
1.51
4.14%
0.06
Dopo l'orario di chiusura:
1.51
Precedente Chiudi:
$1.45
Aprire:
$1.51
Volume 24 ore:
430.82K
Relative Volume:
2.10
Capitalizzazione di mercato:
$47.11M
Reddito:
$81,000
Utile/perdita netta:
$-41.04M
Rapporto P/E:
-1.1466
EPS:
-1.3169
Flusso di cassa netto:
$-30.69M
1 W Prestazione:
+5.59%
1M Prestazione:
+16.15%
6M Prestazione:
-5.03%
1 anno Prestazione:
+20.80%
Intervallo 1D:
$1.47
$1.555
Intervallo di 1 settimana:
$1.3712
$1.555
Portata 52W:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Nome
Actinium Pharmaceuticals Inc
Settore
Industria
Telefono
646-767-3870
Indirizzo
275 Madison Avenue, 7th Floor, New York, NY
Confronta ATNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.51 | 45.23M | 81,000 | -41.04M | -30.69M | -1.3169 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-08-25 | Iniziato | B. Riley Securities | Buy |
| 2020-11-05 | Iniziato | Alliance Global Partners | Buy |
| 2017-12-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | Ripresa | ROTH Capital | Buy |
| 2017-09-14 | Iniziato | Maxim Group | Buy |
| 2016-08-25 | Iniziato | ROTH Capital | Buy |
| 2016-02-29 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2014-10-01 | Iniziato | MLV & Co | Buy |
| 2014-07-22 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Actinium Pharmaceuticals Inc Borsa (ATNM) Ultime notizie
Actinium Pharmaceuticals stock rises after promising breast cancer therapy data - Investing.com
Why Is Actinium Pharmaceuticals Stock Rising Today? - Menafn
Why is Actinium Pharmaceuticals stock rising today? - MSN
Actinium (ATNM) Reveals Promising Preclinical Data for Novel Can - GuruFocus
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br - PR Newswire
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia - openPR.com
Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why - Defense World
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins - openPR.com
Actinium Pharmaceuticals: Clinical Milestone and Promising Data Fuel Oncology Pipeline - AD HOC NEWS
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances - openPR.com
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer - marketscreener.com
ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa - openPR.com
Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa - openPR.com
Can Actinium Pharmaceuticals Inc. (7AY1) stock double in coming yearsJuly 2025 Opening Moves & Safe Entry Point Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock gain from lower interest ratesJuly 2025 Highlights & Risk Controlled Stock Alerts - Newser
Why analysts recommend Actinium Pharmaceuticals Inc. (Delaware) stock2025 Earnings Surprises & Daily Entry Point Trade Alerts - Newser
How Actinium Pharmaceuticals Inc. (Delaware) stock expands through international markets2025 Short Interest & Real-Time Chart Pattern Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock beat Nasdaq index returnsChart Signals & Consistent Profit Alerts - Newser
Why hedge funds are buying Actinium Pharmaceuticals Inc. stockMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Is Actinium Pharmaceuticals Inc. (7AY1) stock a momentum leaderJuly 2025 Volume & Fast Gain Swing Trade Alerts - Newser
Why Actinium Pharmaceuticals Inc. stock is a value investor pick2025 Market WrapUp & Expert Approved Trade Ideas - Newser
Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily
Will Actinium Pharmaceuticals Inc. stock benefit from green energy trendsJobs Report & Daily Entry Point Alerts - Newser
Why retail traders accumulate Actinium Pharmaceuticals Inc. (Delaware) stockJuly 2025 Review & Real-Time Chart Breakout Alerts - Newser
How Actinium Pharmaceuticals Inc. (7AY1) stock valuation compares with sectorQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
How cyclical is Actinium Pharmaceuticals Inc. (7AY1) stock compared to rivalsJuly 2025 Volume & Smart Investment Allocation Insights - Newser
Actinium’s ATNM-400 shows efficacy in resistant breast cancers By Investing.com - Investing.com Australia
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Da - GuruFocus
Actinium's ATNM-400 shows strong efficacy in TNBC, beats therapy resistance at SABCS - marketscreener.com
Actinium’s ATNM-400 shows efficacy in resistant breast cancers - Investing.com
Actinium Pharma details ATNM-400 in resistant breast cancer | ATNM Stock News - Stock Titan
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposiu - PR Newswire
Securities Fraud Class Action Filed Against Actinium Pharmaceutic - The National Law Review
Decliners Report: Will Actinium Pharmaceuticals Inc. stock outperform value stocksCPI Data & Safe Swing Trade Setup Alerts - BỘ NỘI VỤ
Will Actinium Pharmaceuticals Inc. stock outperform Dow Jones index2025 Market Overview & Precise Entry and Exit Recommendations - BỘ NỘI VỤ
Bull Bear: Can Actinium Pharmaceuticals Inc. stock continue upward trend2025 Retail Activity & AI Enhanced Trading Alerts - moha.gov.vn
ROSEN, A LONGSTANDING FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATNM - 28/22 News
Actinium Pharmaceuticals elects directors and approves proposals at annual meeting - Investing.com Australia
Actinium Pharmaceuticals elects directors and approves proposals at annual meeting By Investing.com - Investing.com South Africa
Actinium Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Actinium ATNM holders back board, 3-year say-on-pay cycle - Stock Titan
Why institutional investors increase stakes in Actinium Pharmaceuticals Inc. (7AY1) stock - newser.com
Is Actinium Pharmaceuticals Inc. (Delaware) stock a fit for income portfoliosJuly 2025 Catalysts & Advanced Technical Signal Analysis - newser.com
How Actinium Pharmaceuticals Inc. stock benefits from global expansionMarket Trend Report & Reliable Entry Point Alerts - newser.com
Actinium Pharmaceuticals Inc Azioni (ATNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):